ITGAM维持MAPK信号传递,并作为急性髓性白血病的不良预后因素和治疗标
Chang Zhou1, Lu Yang2, Kai Zhao1
1Department of Ward of Hematopathology, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Translational cancer research
|July 11, 2024
概括
在急性髓性白血病 (AML) 患者中,整合素子单元αM (ITGAM) 升高,与生存率差相关. 针对ITGAM可能通过抑制细胞增殖和通过MAPK途径诱导亡,为AML提供新的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 尽管有基因的进步,急性髓性白血病 (AML) 的预后不好.
- 确定AML的新疗法标和诊断标记是非常重要的.
- 了解潜在的反洗钱目标的行动机制至关重要.
研究的目的:
- 调查整合素亚单元αM (ITGAM) 在AML中的作用.
- 评估ITGAM作为AML的预后生物标志物和治疗标.
- 探索ITGAM在AML中的功能背后的分子机制.
主要方法:
- 使用人类蛋白质图谱和GEPIA数据库分析ITGAM表达式.
- 使用癌症基因组图谱 (TCGA) 评估的预后相关性.
- 在体外评估的ITGAM对AML细胞增殖和亡的功能影响.
- 进行了基因本体学 (GO) 和基因和基因组 (KEGG) 的京都百科全书的途径分析.
主要成果:
- 与对照组相比,在AML患者样本中,ITGAM表达显著更高.
- 升高的ITGAM表达与AML患者的整体存活率 (OS) 较差有关.
- ITGAM knockdown 减少了AML细胞的扩散,诱导了亡,并导致G1阶段细胞循环停止.
- ITGAM通过影响p38,JNK和ERK酸化来积极调节MAPK信号.
结论:
- ITGAM作为一个潜在的预后生物标志物和AML的治疗点.
- 沉默ITGAM抑制AML细胞活力,并通过阻碍MAPK通路激活诱导细胞亡.
- 针对ITGAM-MAPK轴提出了一种新的AML治疗和克服化学抵抗的战略.
更多相关视频
相关概念视频
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:07MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K